Verve TherapeuticsVERV
13F holders, Q3 2025 (September 30)6holders −169
0new positions
169sold out
$5.42avg. 13F price*
At the end of Q3 2025, 6 institutions reported holding Verve Therapeutics Inc. (VERV) in their 13F filings, down 169 from Q2 2025. 0 opened new positions and 169 sold out. The largest holders were Greenland Capital Management LP ($556K), DekaBank Deutsche Girozentrale ($341K) and Brooklyn Investment Group ($197K).
- Company
- Verve Therapeutics Inc.
- CUSIP
- 92539P101
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 169 | $817.7M |
All 13F filers, Q2 2025 → Q3 2025: 86,596 shares bought and 72,814,253 shares sold, net −72,727,657 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Greenland Capital Management LP | 0.09% | No change | 49,506 | $556K |
| DekaBank Deutsche Girozentrale | 0.00% | No change | 24,000 | $341K |
| Brooklyn Investment Group | 0.03% | No change | 17,417 | $197K |
| IFP Advisors, Inc | 0.00% | Add +4.0% | 10,026 | $112K |
| Osaic Holdings, Inc. | 0.00% | Reduce -3.5% | 3,344 | $38K |
| XTX Topco Ltd | 0.00% | Add +222.4% | 124,964 | $0 |
"% of holder's portfolio" is VERV's weight in each manager's 13F, not the share of Verve Therapeutics Inc. the manager owns.